MK-0633, a potent 5-lipoxygenase inhibitor, in chronic obstructive pulmonary disease  by Bernstein, Jonathan A. et al.
Respiratory Medicine (2011) 105, 392e401ava i lab le at www.sc iencedi rect .com
journal homepage : www.e lsev ie r . com/ loca te / rmedMK-0633, a potent 5-lipoxygenase inhibitor,
in chronic obstructive pulmonary diseaseJonathan A. Bernstein a,*, Nancy Liu b, Barbara A. Knorr b,
Steven S. Smugar b, William D. Hanley b, Theodore F. Reiss b,1,
Steven Greenberg baBernstein Allergy Group, Bernstein Clinical Research Center, Inc. 8444 Winton Rd, Cincinnati, OH 45231, USA
bMerck & Co., Inc., PO Box 100, Whitehouse Station, NJ 08889, USA
Received 2 August 2010; accepted 29 September 2010
Available online 13 November 2010KEYWORDS
5-Lipoxygenase;
Chronic obstructive
pulmonary disease;
Forced expiratory
volume in 1 s;
Lung function* Corresponding author. Tel.: þ1 51
E-mail address: jonathan.bernstei
1 Current employer: Covance, Inc.,
0954-6111/$ - see front matter ª 201
doi:10.1016/j.rmed.2010.09.021Summary
Chronic obstructive pulmonary disease (COPD) is associated with neutrophil-mediated inflam-
mation, a potential target for treatment in COPD. We evaluated MK-0633, a 5-lipoxygenase
inhibitor in patients with COPD.
This was a 12 week, randomized, double-blind, multicenter study comparing MK-
0633 100 mg and placebo in patients 40e75 years of age (N Z 266) with COPD, post-b-agonist
forced expiratory volume in 1 s (FEV1) 25%e75% predicted, and an FEV1/forced vital capacity
ratio (FVC) 70%. Long-acting inhaled bronchodilators were permitted for approximately 50%
of patients. The primary efficacy endpoint was the change from baseline in pre-dose (trough)
FEV1 measured over the last 2 weeks of the 12 week treatment period.
The change in FEV1 over the last 2 weeks of the 12 weeks treatment period compared to
baseline was 0.015 L for MK-0633 and 0.0002 for placebo (p Z 0.556). For COPD Global Eval-
uation, 75.4% of patients receiving MK-0633 reported feeling better vs. 59.8% of patients
receiving placebo (p Z 0.032). There were no other significant differences between treat-
ments. MK-0633 was well-tolerated and comparable to placebo.
The 5-LO inhibitor MK-0633 was not significantly more effective than placebo in improving
FEV1 from baseline in patients with COPD, although more patients reported feeling improved
with MK-0633.
Clinicaltrials.gov identifier: NCT00418613.
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Chronic obstructive pulmonary disease (COPD) is the 4th
leading cause of death worldwide1 and a source of
substantial economic and social burden that has been
steadily increasing. COPD is characterized by inflammation,
parenchymal tissue destruction, mucus hypersecretion, and
airflow limitation that is not fully reversible.2 The under-
lying inflammation seen with COPD, particularly the small
airways, includes macrophages, neutrophils, CD4 and CD8-
positive T-cells, and B-cells.3 Leukotriene B4 (LTB4),
a potent chemoattractant of both neutrophils and T-cells,4
is thought to be an important mediator of neutrophil
recruitment and survival in COPD,5, 6 and increased levels
have been shown in serum,7 induced sputum,8 and exhaled
breath condensates9 in patients with COPD. Therefore,
drugs that target LTB4 production could potentially reduce
inflammation in COPD.
Indeed, a trial of a 5-lipoxygenase activating protein
(FLAP) inhibitor led to trends in decreased concentrations
of LTB4 and myeloperoxidase, a marker of neutrophils, and
decreased neutrophil chemotactic activity in sputa obtained
from COPD patients.10 In addition, antibiotic treatment of
patients with acute bacterial exacerbation of COPD reduced
sputum LTB4, which was accompanied by a reduction of
w30% of sputum chemotactic activity attributed to LTB4.
11
Zileuton, a 5-LO inhibitor, and the only commercially avail-
able agent that acts on the LTB4 pathway, has been shown to
decrease LTB4 levels in patients with asthma, and signifi-
cantly increase exercise capacity and quality of life in
patients with COPD.12 However, results directly implicating
LTB4 in COPD pathogenesis have been somewhat inconsis-
tent.13 The purpose of this study was to evaluate MK-0633,
a 5-LO inhibitor, in patients with COPD.
Methods
Patients
Men and postmenopausal women age 40e75 years with
a history consistent with COPD for at least 1 year were
eligible. Eligible patients had a post-b-agonist forced
expiratory volume in 1 s (FEV1)/forced vital capacity (FVC)
ratio 70% and FEV1 25e75% of the predicted value,
smoking history of 10 pack-years, and a body mass index
of 19e40 kg/m2.
Pertinent exclusion criteria included a clinically signifi-
cant active pulmonary disorder (other than COPD); emer-
gency room treatment or hospitalization for COPD within
the previous 2 months; oxygen saturation on room air
<88% while withholding b-agonist for at least 6 h; continuous
(>16 h/day) oxygen therapy; uncontrolled hypertension
(>160/100 mmHg); or myocardial infarction, congestive
heart failure, or uncontrolled cardiac arrhythmia within 3
months. Excluded COPDmedications included oral or inhaled
short-acting anticholinergic agents within 2 weeks; oral
or inhaled long-acting bronchodilators within 2 weeks
(if patient is not within the 50% of patients permitted per site
to receive long-acting bronchodilators); antileukotriene
medications, intravenous or intramuscular corticosteroids
within 3 weeks; xanthine derivatives or combinations within2weeks; or oral or inhaled corticosteroids within 2weeks. An
action plan for worsening COPD was provided.
To assess whether MK-0633 may have an additive benefit
to long-acting bronchodilators, as well as to ensure that the
sample population was representative of the COPD pop-
ulation, up to 50% of patients randomized at each site were
allowed to receive chronic stable doses of long-acting
bronchodilators (e.g., tiotropium, salmeterol) during the
trial. All patients were permitted to use an inhaled short-
acting b-agonist throughout the study on an “as needed”
basis for relief of COPD symptoms.
Study Design
This study (Merck protocol 009) was a 12 week, multicenter,
randomized, double-blind, placebo-controlled, parallel
group study of the efficacy of MK-0633 in COPD, conducted
at 36 sites from January 2008 to March 2009. The conduct of
this study was consistent with the standards of the Decla-
ration of Helsinki. The protocol was approved by local
institutional review boards or ethics committees, and
patients provided written informed consent prior to
participation.
During a 2-week, single-blind placebo run-in period,
patients were required to have daytime and nighttime
b-agonist administration weekly average 5 puffs per week
and an average overall daytime symptoms score of 1.2
(based on symptom frequency, scored from 0Z “none of the
time” to 5Z “all of the time”), and demonstrate at least 80%
compliance with test drug. After the run-in, eligible patients
were randomized to receive once-daily MK-0633 100 mg or
matching placebo eachmorning for 12 weeks. Allocation was
determined according to a computer-generated allocation
schedule. Numbered packaging was used to implement
allocation. All studypersonnel, including investigators, study
site personnel, patients, monitors, and central laboratory
personnel remained blinded to treatment allocation
throughout the study. The code was revealed to the
researchers once recruitment, data collection, and labora-
tory analyses were complete.
Efficacy and Tolerability Assessments
Spirometry was performed at baseline/randomization and
at weeks 2, 4, 8, 10, and 12 between 6 AM and 10:30 AM
after withholding the morning dose of study medication and
short-acting b-agonists for at least 6 h, LABA for at least
12 h, and long-acting anticholinergic agents for 24 h.
Reversibility was measured by administering two puffs of
a short-acting b-agonist and performing spirometry
20e30 min afterward. A daily patient diary was used to
capture daytime and nighttime symptoms, b-agonist use,
peak expiratory flow rate (PEFR), and daytime COPD
resource utilization. Daytime symptoms were assessed with
6 questions, all scored on a 6-point Likert scale: 1) Overall
daytime symptom frequency; 2) Shortness of breath
frequency; and 3) Cough frequency, all scored from
0 Z “None of the time” to 5 Z “All of the time”; 4) Mucus
production, scored from 0Z “None” to 5Z “A very large or
massive amount”; 5) Difficulty performing routine activities
requiring light physical movement (e.g., bathing); and 6)
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(e.g., walking up stairs), both scored 0Z “No difficulty” to
5 Z “So difficult, couldn’t do it at all”. Nighttime symp-
toms were assessed by quantitating awakenings due to lung
symptoms (0, 1, 2, 3 or more). PEFR was measured imme-
diately before bedtime and immediately upon awakening
before taking study medication or concomitant medica-
tions. COPD resource utilization was recorded in the diary
by asking the question “In the past 24 h, did you call
a doctor; or visit a doctor, emergency room or hospital; or
take additional medications (including corticosteroid pills)
due to a worsening of your lung disease?” Patients also
completed a global COPD evaluation at 12 weeks (or
discontinuation) consisting of a single question describing
patients’ perception of the change in their COPD over the
course of the study (“Very much better,” “Moderately
better,” “A little better,” “Unchanged,” “A little worse,”
“Moderately worse,” “Very much worse”). Patients
completed the self-assessed standardized version of the
chronic respiratory disease questionnaire (CRQ-SAS)14, 15 at
baseline and at Weeks 8 and 12.
The primary efficacy endpoint was change from base-
line (i.e., randomization) in pre-dose (trough) FEV1
measured over the last two weeks of the 12 week active
treatment period. The rationale for analyzing the last
two weeks was because of the limited data available for
MK-0633 and 5-LO inhibitors in general regarding when
the maximal effect of a 5-LO inhibitor would be achieved
in COPD. Secondary endpoints were overall daytime
symptoms scores, post-dose FEV1, total daily b-agonist
use, dyspnea, and CRQ score, measured over a 12 week
treatment period. Exploratory endpoints included AM and
PM PEFR, individual daytime COPD symptom scores,
nocturnal awakenings, and COPD exacerbations (defined
according to resource utilization, including the need for
additional rescue medications [systemic corticosteroids
and/or antibiotics] or unscheduled COPD-related doctor
visits, emergency department visits or hospitalizations).
Other exploratory endpoints were patient Global Evalua-
tion, COPD symptom-free days (overall symptom score of
0 or 1), pre-dose (trough) FVC, and post-b-agonist FEV1
and FVC. A portion of patients at participating sites were
also enrolled in a whole body plethysmography lung
volume sub-study, with measurements made at baseline
and 12 weeks.
Tolerability was assessed by physical and laboratory
examinations, vital signs, and incidence of adverse expe-
riences (AEs). Because of a suggestion of renal tubular
damage in mice in acute toxicity studies, an internal data
safety monitoring committee reviewed results of an
interim blinded safety analysis of urine N-acetyl-b-gluco-
saminidase (NAG), a sensitive marker of acute tubular
injury,16 as well as other markers of renal function, after
50% of patients completed the main study. Patients
with NAG >3x baseline value on 2 consecutive measure-
ments were discontinued. The committee also evaluated
patients with significant increases NAG or urinary micro-
albumin that did not achieve the 2- or 3-fold levels
for discontinuation to determine if elevations met pre-
specified criteria for study termination. Patients with ALT
or AST 3 ULN or on 2 consecutive occasions were also
discontinued.Pharmacokinetic (PK) measurements
Plasma samples were collected for MK-0633 assay at pre-
study and at week 8, pre-dose and at 4 h post-dose. If
possible, patients fasted over-night, or at least 8 h prior to
these visits. The analytical method for determination of
MK-0633 in human plasma involved isolation, via 96-well
protein precipitation, of the analyte and internal standard
in plasma, followed by reverse phase high pressure liquid
chromatography tandem mass spectrometry analysis. The
lower limit of quantitation (LLOQ) for the plasma assay was
5 nM and the linear calibration range was 5e5000 nM. The
pre-dose and 4 h post-dose MK-0633 concentrations at week
6 were assessed from plasma concentrations at nominal
sampling times and not corrected based on when the dose
was administered or when the samples were actually
collected. Urinary LTE4 samples were collected at baseline
and Week 8.Statistical methods
The primary hypothesis was that MK-0633, compared with
placebo, would result in significant improvement in FEV1
measured over the last 2 weeks of a 12 week treatment
period in patients with COPD. The primary efficacy analysis
was based on the Full Analysis Set population, which
included all randomized patients with a baseline
measurement and at least one post-treatment measure-
ment. A per-protocol analysis was also performed. The
primary endpoint was analyzed using a longitudinal linear
model, with change from baseline in FEV1 at each visit as
the dependent variable and treatment, study country,
concomitant long-acting bronchodilator use, smoking
status, baseline FEV1 reversibility, baseline FEV1, and
treatment-by-visit interaction as independent variables.
The covariance across visits within each subject was
modeled using a general unstructured covariance matrix.
The primary analyses were based on observed data, and
missing data were not imputed. Pre-specified subgroup
analyses of the primary endpoint included long-acting
bronchodilator use, gender, age group (40 to <50, 50 to
<65, 65e75 years), ethnicity (white, black, Hispanic,
other), smoking history (current smoker, ex-smoker), region
(US/Canada, Central/South America, Europe, Japan,
other), baseline severity based on baseline FEV1% predicted
(50% Z moderate; <50% Z severe); and baseline FEV1
reversibility to b-agonist (low reversibility Z 12%; high
reversibility >12%). Additional post-hoc analyses of
secondary and exploratory endpoints were performed for
these same pre-specified subgroups.
Between-group comparisons of the proportion of patients
with at least one COPDexacerbationwere analyzed using the
Fisher Exact test. The KaplaneMeier procedure was used to
estimate and the log-rank testwas used to compare the time-
to-first COPD exacerbation curves. The percentage of COPD
symptom-free days over the last 2 weeks of treatment was
analyzed using an analysis of covariance (ANCOVA) model
with factors for treatment, study country, concomitant log-
acting bronchodilator use, smoking status, baseline FEV1
reversibility, and baseline percentage of COPD symptom-
free days. The proportion of patients in each category of
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Figure 1 Patient flow through the study. )Two patients dis-
continued due to AEs that began prior to randomization. A total
of three patients receiving MK-0633 discontinued due to post-
randomization AEs.
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CochraneManteleHaenszel test.
Tolerability analyses were based on the All Patients as
Treated population, which included all randomized patients
who received at least one dose of study medication.
Patients were included in the treatment group corre-
sponding to the study medication actually received, irre-
spective of the group to which they were randomized.
Between-group differences in AEs were determined by the
Miettinen and Nurminen method.17 Formal statistical
testing (i.e., p-values) was performed only for urinary NAG
and microalbumin endpoints. For other AEs, the incidence
and 95% confidence intervals were calculated.
It was expected that the difference between groups
would be approximately 80 mL in the subgroup of patients
not receiving long-acting bronchodilators (approximately
50% of patients) and 48 mL in the subgroup receiving
bronchodilators. With 100 evaluable patients per group, the
study had 80% power (aZ 0.05, two-sided t-test) to detect
an overall difference of 64 mL between MK-0633 and
placebo in the change from baseline in FEV1, assuming
a standard deviation of 160 mL. Secondary results were only
tested if the primary endpoint was significant at the 0.05
level. However, because the secondary results were
supportive in nature, no adjustments for p-values were
made.
After results unblinding, data revealed two outliers,
both in the MK-0633 group, whose improvement in FEV1
greatly exceeded that of all other patients. Based on
review of spirometry data, it was concluded that these two
patients were experiencing acute COPD exacerbations at
baseline (FEV1: 1.67 L and 1.96 L) and that their clinical
improvements (1.62 and 2.18 L, respectively) were due to
resolution of their exacerbations. Thus, these two patients
have been excluded from the efficacy analyses.
Results
Patients
Approximately 90% of patients in each group completed
the study; the most common reason for discontinuation
was an adverse experience (Fig. 1). Approximately 98% of
patients in each group were included in the primary effi-
cacy analysis, and all but one patient (in the MK-0633
group) were included in the safety analyses. Most patients
were white and male, and the mean age was approxi-
mately 63 years (Table 1). Although there were some
numerical differences in baseline characteristics (e.g.,
age), patients in both treatment groups were generally
similar.
Efficacy
For the primary efficacy endpoint of change from baseline
in pre-dose (trough) FEV1 over the last two weeks of the
12 week treatment period, there was no statistically
significantly difference between MK-0633 and placebo
(least squares (LS) means 0.015 L vs. 0.002 L; p Z 0.556)
(Table 2), although there were numerical improvements
over the entire 12 week period (Fig. 2). Results for the fullanalysis population including the two outlier patients
showed a larger treatment effect for MK-0633 compared
with placebo, but the difference was not statistically
significant (0.038 L vs. 0.005 L; p Z 0.205).
The pre-specified subgroup analyses of the primary
endpoint showed trends toward greater improvements with
MK-0633 vs. placebo in patients receiving long-acting
bronchodilators, patients from Central/South America,
patients between 50 and 65 years of age, and in patients
with reversibility >12% (Fig. 3), although none of these
factors had a significant effect on the main outcome as
determined by the ANCOVA model.
There were no significant differences in the secondary
endpoints of overall daytime symptoms scores, average
total daily b-agonist use, overall CRQ, individual CRQ
domains (data not shown), or in the exploratory endpoints
of AM or PM PEFR, nocturnal awakenings, COPD symptom-
free days, (Table 2) or COPD exacerbations or time to first
COPD exacerbation (Fig. 4). There were no significant
differences for the change from baseline in the individual
daytime symptoms scores (data not shown), although the
changes for MK-0633 vs. placebo approached significance
for patient-reported amount of time coughed (LS mean
0.21 vs. 0.07; pZ 0.087), and patient-reported amount
of mucus (LS mean 0.25 vs. 0.08; p Z 0.054).
Patients receiving MK-0633 reported significantly greater
COPD Global Evaluation scores at Week 12 than those
receiving placebo (p Z 0.001) (Table 3). There was
a significant (pZ 0.032) shift in the distribution of patients
toward better response for MK-0633 vs. placebo.
There were no significant differences in changes in pre-
dose FVC, or post-b-agonist FEV1 or FVC (Table 2), and
serial spirometry at 1, 2, and 4 h post-dose showed no
Table 1 Baseline patient characteristics.
MK-0633 100 mg Placebo
N Z 132 N Z 133
Age (years)
Mean (SD) 63.3 (7.2) 62.9 (7.6)
Range 45.0 to 75.0 40.0 to 75.0
Age group, n (%)
40 to <50 6 (4.5) 7 (5.3)
50 to <65 59 (44.4) 67 (50.4)
65 to 75 68 (51.1) 59 (44.4)
Gender, n (%)
Female 45 (33.8) 33 (24.8)
Male 88 (66.2) 100 (75.2)
Race, n (%)
Asian 15 (11.3) 17 (12.8)
Black 5 (3.8) 3 (2.3)
Native American 1 (0.8) 0 (0.0)
White 112 (84.2) 113 (85.0)
Smoking history, n(%)
Current smoker 63 (47.4) 60 (45.1)
Ex-smoker 70 (52.6) 73 (54.9)
Pack-years, mean (SD) 50.2 (24.6) 48.8 (26.3)
FEV1
L, mean (SD) 1.31 (0.45) 1.38 (0.54)
% predicted, mean (SD) 44.37 (13.45) 44.53 (14.49)
Post-b-agonist (L), mean (SD) 1.46 (0.49) 1.53 (0.58)
FVC (L), mean (SD) 2.66 (0.72) 2.72 (0.80)
FEV1/FVC ratio (%), mean (SD) 49.98 (11.02) 51.25 (12.17)
Concomitant chronic long-acting bronchodilator use, n (%) 58 (43.6) 57 (42.9)
Reversibility at screening, n (%)
12% 79 (59.4) 83 (62.4)
>12% 54 (40.6) 50 (37.6)
Mean (SD) 10.58 (12.16) 10.59 (11.30)
Reversiblea patients, n (%) 41 (30.8) 37 (27.8)
a Reversible defined as reversibility >12% and an increase >0.2 L.
396 J.A. Bernstein et al.significant differences between MK-0633 and placebo for
post-dose FEV1 or FVC (data not shown).
Post-hoc subgroup analyses
Additional post-hoc analyses were carried out for the pre-
specified subgroup based on concomitant long-acting
bronchodilator use. Differences between MK-0633 and
placebo were substantially greater in patients receiving
long-acting bronchodilators than in those not receiving
long-acting bronchodilators, for patient-reported shortness
of breath (0.11 vs. 0.01), patient-reported amount of
mucus (0.24 vs. 0.13), patient-reported difficulty in
performing light physical activity (0.15 vs. 0.05),
patient-reported difficulty in performing moderate/high
physical activity (0.36, vs. 0.03), and CRQ (0.24 vs.
0.13).
Lung volume sub-study
A total of 134 patients participated in the sub-study, 71 in
the MK-0633 group and 63 in the placebo group. Of these,
only 100 patients (51 in the MK-0633 group and 40 in theplacebo group) had both baseline and at least one post-
randomization measurement. Only these patients were
included in the sub-study. There were no significant
differences from baseline in total lung capacity, thoracic
gas volume at functional residual capacity, expiratory
reserve volume, inspiratory capacity, residual volume,
slow vital capacity, and airway resistance (data not
shown).
Pharmacokinetic-pharmacodynamic analyses
Mean MK-0633 plasma levels at week 6 were approximately
1935.5 nM pre-dose and 3773.1 nM at 4 h post-dose.
Urinary LTE4/creatinine ratio was reduced by 90% from
baseline, from a mean of 96.98 pg/mg to 8.80 pg/mg while
the mean change in urinary LTE4/creatinine in the placebo
group increased from 85.16 pg/mg to 93.90 pg/mg.
Maximal inhibition of LTE4 (90%) was associated with MK-
0633 trough plasma levels of approximately 1200 nM and
higher (Fig. 5a). However, drug plasma levels of MK-0633
associated with maximal inhibition of LTE4 were not
associated with greater improvements in FEV1 at Week 8
(Fig. 5b).
Table 2 Efficacy results.
N Baseline
(mean [SD])
Change from baseline
(LS mean [95% CI])
Difference
(LS mean [95% CI])
P
PRIMARY ENDPOINT
Average change from baseline in pre-dose (trough) FEV1 (L)
MK-0633 127 1.30 (0.45) 0.015 (0.017, 0.048) 0.013 (0.030, 0.056) 0.556
Placebo 131 1.37 (0.53) 0.002 (0.030, 0.034)
SECONDARY ENDPOINTS
Average change in overall daytime symptoms score
MK-0633 117 2.10 (0.66) 0.17(0.28,0.06) 0.04(0.19,0.11) 0.592
Placebo 121 2.05 (0.57) 0.13(0.24,0.02)
Average change in total daily b-agonist use (puffs/day)
MK-0633 117 4.76 (3.34) 0.44(0.94,0.07) 0.12(0.81,0.56) 0.721
Placebo 122 4.36 (3.89) 0.31(0.80,0.18)
Average change in CRQ score (all domains) at Week 12
MK-0633 118 4.77 (0.98) 0.19 (0.04, 0.35) 0.05 (0.16, 0.25) 0.653
Placebo 118 4.80 (0.98) 0.15 (0.01, 0.30)
EXPLORATORY ENDPOINTS
Average change in AM PEFR (L/min)
MK-0633 117 220.96 (73.02) 8.73 (3.03, 14.43) 7.09 (0.68, 14.86) 0.074
Placebo 122 237.37 (86.04) 1.64 (3.94, 7.21)
Average change in PM PEFR (L/min)
MK-0633 117 233.94 (75.88) 8.85 (2.64, 15.05) 5.21 (3.26, 13.68) 0.227
Placebo 122 244.09 (86.94) 3.64 (2.44, 9.72)
Nocturnal awakenings in patients who had at least 1 night with awakening per week
MK-0633 78 0.96 (0.85) 0.29(0.41,0.18) 0.06(0.21,0.09) 0.450
Placebo 81 0.94 (0.71) 0.23(0.34,0.12)
COPD symptom-free days (%) over 12 weeks
MK-0633 128 19.44 (27.61) 8.206 (1.895, 14.518) 2.982 (5.205, 11.169) 0.474
Placebo 132 20.07 (26.90) 5.225 (0.952, 11.402)
Pre-dose FVC (L)
MK-0633 127 2.63 (0.69) 0.013 (0.063, 0.089) 0.031 (0.070, 0.133) 0.548
Placebo 131 2.71 (0.80) 0.018(0.092,0.057)
Post-b-agonist FEV1 (L)
MK-0633 117 1.44 (0.50) 0.004 (0.033, 0.040) 0.021 (0.028, 0.069) 0.400
Placebo 118 1.50 (0.56) 0.017(0.053,0.019)
Post-b-agonist FVC (L)
MK-0633 117 2.84 (0.83) 0.016(0.097,0.065) 0.010 (0.097, 0.116) 0.857
Placebo 118 2.94 (0.84) 0.025(0.104,0.053)
Unless noted otherwise, all endpoints are measured over the last 2 weeks of the 12 week treatment period unless otherwise noted. All
analyses exclude the two outlier patients.
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Figure 2 Primary endpoint: Change from baseline in pre-
dose (trough) FEV1 (L).
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MK-0633 was well-tolerated and there were no significant or
clinically meaningful differences in the rates of AEs
compared with placebo (Table 4). The most common AEs
were nasopharyngitis, pneumonia, and COPD. There were
a total of 10 patients experiencing 13 serious AEs; 6
patients in the MK-0633 group (hypoxemia, coronary artery
disease, cataract, ileus, acute pharyngitis, pneumonia,
urinary retention, COPD exacerbation) and 4 in the placebo
group (gastrointestinal arteriovenous malformation, chest
discomfort, chest pain, pneumonia, sepsis). None of the
serious AEs were considered by the investigator to be drug-
related. One patient receiving MK-0633 died while partici-
pating in study due to a COPD exacerbation and multilobar
pneumonia, which were determined by the investigator not
to be drug-related.
Treatment Difference and 95% CI
-0.3 0.0 0.3
Baseline Reversibility: >12%
Baseline Reversibility: <=12%
Baseline Severity: % predict FEV1>=50%
Baseline Severity: % predict FEV1<50%
Region: Japan
Region: Europe
Region: Central/South America
Region: US/Canada
Smoking History: EX-SMOKER
Smoking History: CURRENT SMOKER
Gender: Female
Gender: Male
Age: 65<= age <=75
Age: 50<= age <65
Race: ASIAN
Race: WHITE
Concomitant Stratum: Patient not on LABD
Concomitant Stratum: Patient on LABD
Figure 3 Prespecified subgroup analysis of the change from
baseline in trough FEV1(L).
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and placebo for NAG discontinuations (0 discontinuations in
both groups) (Table 4), or the absolute change or distribution
of percentage change frombaseline in urinary NAG or urinary
microalbumin (data not shown). However, there was
a borderline significant difference for MK-0633 comparedPatients at Risk 
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Figure 4 KaplaneMeier plot of time to first COPD exacer-
bation. A total of 17 (13.1%) of patients in the MK-0633 group
and 20 (15.0%) in the placebo group had COPD exacerbations.
The KaplaneMeier estimates (% [95% CI)]) at Week 12 were
12.3% (7.2, 18.8) and 15.9% (10.1, 22.8), respectively. The
difference was 3.6 (12.2, 5.1); pZ 0.425 vs. placebo based
on Log Rank Test. 95% confidence intervals based on the
logelog transformation.with placebo in the percent change from baseline in
urinary NAG (LS mean change 14.4% vs. 2.3%, respectively;
pZ 0.074). There were no significant differences between
MK-0633 and placebo for changes frombaseline in blood urea
nitrogen or creatinine. In addition, there were no significant
or clinically meaningful differences between MK-0633 and
placebo for elevations in AST or ALT.
Discussion
In this Phase IIa proof-of-concept study, MK-0633, a 5-LO
inhibitor, was not significantly more effective than placebo
in improving pre-dose, pre-bronchodilator FEV1 from base-
line after 12 weeks of treatment in patients with COPD.
There were numerical differences in some of the pre-speci-
fied subgroup analyses of the primary endpoint. Notably,
differences from placebo with MK-0633 were larger in
patients with baseline reversibility >12%, patients from
Central/South America, and patients on concomitant long-
acting bronchodilators. It was previously shown in studies of
LABAs that lung function response is greater in COPD patients
with greater reversibility,18 which may account for the
greater response to MK-0633 in this subgroup. Of note is that
60% of patients from Central/South America had a baseline
reversibility >12%, which likely accounts for the greater
response vs. placebo in that subgroup. In addition, a greater
percentage of patients using concomitant long-acting bron-
chodilators compared with non-users had a high degree of
reversibility (42% vs. 36%), which might have partially
contributed to the apparently greater improvement in
multiple endpoints in this subgroup.
We did not observe significant differences between
MK-0633 and placebo for any of the secondary and explor-
atory endpoints, with the exception of patient Global Eval-
uation. The greater percentage of patients reporting overall
improvement in the MK-0633 group may have reflected
numerical improvements in the individual daytime symptoms
of amount of time coughed and amount of mucus in this
subgroup. Both cough and mucus have been shown to be
associatedwithworsequality of life in COPD19,20 andboth are
highly tangible measures of disease activity that patients
may perceive more readily than changes in lung function
measures. These findings would need to be confirmed in
a prospective study.
We also did not observe any between-treatment
differences in the lung function sub-study, which is
consistent with the spirometry results in the main study.
However, it is nonetheless worth noting that 84% of
participants were from Europe, only 35% of whom had
baseline reversibility 12%. Thus, the disproportionately
low reversibility in these patients may have accounted, in
part, for the apparent lack of efficacy of MK-0633 in the
sub-study.
The inflammatory pattern and findings in COPD airways
(i.e., neutrophilic, and associated with increased LTB4
4e6)
provided a pathophysiologic basis for targeting LTB4
activity in COPD.21 In Phase I data of MK-0633 in healthy
adult subjects, doses of 100 mg/day provided continuous
and complete LTB4 inhibition in ex vivo whole-blood
assays, and reduced urinary LTE4 levels to <10 pg/mg
creatinine, which correlated with an LTE4 inhibition of
approximately 90% or higher (data on file). In the present
Table 3 Patient Global Evaluation at Week 12.
Overall Score N LS Mean (95% CI) Difference(LS mean [95% CI]) P
MK-0633 115 1.45 (1.22, 1.68) 0.50 (0.20, 0.80) 0.001
Placebo 122 0.95 (0.72, 1.17)
Evaluation Category Better N (%) Unchanged N (%)
MK-0633 122 92 (75.4) 22 (18.0) 0.032*
Placebo 127 76 (59.8) 36 (28.3)
*p-value for pairwise comparison based on CochraneManteleHaenszel test.
MK-0633, a potent 5-LO inhibitor, in COPD 399study, the mean trough plasma level of MK-0633 was
1935.5 nM, which was sufficient to inhibit mean urinary
LTE4/Cr by >90%. Despite this marked decrease in an
accepted biomarker of 5-LO activity, there were no
greater increases in change from baseline in FEV1 over the
range of drug exposures evaluated here. It is possible that
MK-0633 plasma levels, and the corresponding extent of
enzymatic inhibition observed in this study were insuffi-
cient to achieve maximal clinical efficacy. For example,
the urinary concentration of LTE4 reflects total body
production and metabolism of LTE4. It is possible, if not
likely, that concentrations of products of the 5-LO
pathway are much higher at sites of inflammation, such as
the small airways, implying that urinary LTE4/Cr is a pooroit
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Figure 5 Relationship of pre-dose plasma concentration of
MK-0633 (nM) to urinary LTE4/creatinine ratio (pg/mg) (A) and
change from baseline in FEV1 (B) at Week 8.surrogate biomarker for lung LTE4 concentrations.It is also
possible that in COPD patients, only some aspects of
disease (e.g., mucus production, but not bronchocon-
striction) are driven by either LTE4 or other metabolites of
the 5-LO pathway, such as LTB4. Indeed, the greater
apparent responses to MK-0633 in patients with
greater reversibility at baseline may reflect not only
a greater intrinsic capacity for bronchodilation, but also
a greater dependency on the 5-LO pathway for airway
inflammation in this subgroup.
We are aware of only two studies of drugs that act on
LTB4 that assessed clinical endpoints in patients with
COPD. Gronke and colleagues evaluated LTB019, an LTB4
receptor antagonist, in 24 patients with COPD, and
found no significant difference from placebo in sputum
neutrophils or related cytokines, use of rescue medica-
tion, or FEV1 or FVC.
13 The authors hypothesized that
based on the lack of effect on neutrophils, mediators
other than LTB4 may have been primarily responsible for
neutrophil recruitment in the lungs of their patients,
and/or other cytokines compensated for LTB4 via
parallel pathways. Berger and colleagues reported on
a trial of 8 patients with COPD, in which the 5-LO
inhibitor zileuton significantly improved exercise
capacity as measured by the 6-min walk test compared
with placebo, as well as quality of life and COPD ques-
tionnaire scores. However, spirometric endpoints such as
FEV1 were not reported.
12
There have been few prospective trials of other anti-
leukotriene agents in COPD. Cazzola and colleagues eval-
uated double-blinded zafirlukast and placebo in 16
patients with COPD, and found a significant improvement
in bronchodilation with zafirlukast 30 min to 4 h after
administration, with a mean maximum increase in FEV1 of
0.14 L.22 In a randomized, single-blind non-placebo
controlled trial of 117 patients, the addition of mon-
telukast to ipratropium and formoterol resulted in signifi-
cant changes from baseline in FEV1, FVC, oxygen
saturation, and quality of life, but there were no such
changes in patients receiving ipratropium and formoterol
only.23 The sum of the available clinical evidence of anti-
leukotrienes in COPD has been inconsistent and based on
small trials, with at best modest effects on symptoms and
lung function that have yet to be confirmed in large
randomized clinical trials. A possible explanation for the
apparent limited efficacy of leukotriene antagonists in
COPD is that by the time COPD has become clinically
apparent, the disease is already moderately advanced,24
with irreversible parenchymal damage, thus limiting the
Table 4 Adverse experiences (clinical and laboratory).
MK-0633 Placebo
N Z 132 N Z 133
Any adverse experience 56 (42.4) 63 (47.4)
Drug-related adverse
experience
12 (9.1) 14 (10.5)
Serious adverse experience 6 (4.5) 4 (3.0)
Discontinuation due to adverse
experience
3 (2.3) 5 (3.8)
Discontinuations due to NAG
criteriona
0 (0.0) 0 (0.0)
a Levels >3x upper limit of normal on 2 consecutive occasions; NAG Z N-acetyl-b-glucosaminidase.
400 J.A. Bernstein et al.benefits of anti-inflammatory treatments alone, particu-
larly with respect to lung function. These results further
emphasize both the difficulty in effectively managing
COPD and, perhaps, the need to move beyond the asthma
treatment paradigm in targeting COPD treatment. Given
the findings of montelukast add-on in COPD23 and the
trends we observed in the present study in patients
receiving long-acting bronchodilators, particularly with
respect to mucus production and physical activity, it is
possible that agents such as 5-LO inhibitors could have
a role as adjunctive therapy in this disease. However,
further prospective studies are required.
A limitation of this study is that we did not assess
markers of airway inflammation. As noted above, previous
studies of other compounds targeting the LTB4 receptor
have shown improvements in such markers,10,11 although
results were not consistent.13 Preclinical research with MK-
0633 suggested that urinary LTE4 was a reasonable surro-
gate endpoint for LTB4 production, but as discussed, this
may not accurately reflect cysteinyl leukotrienes in the
lung. Assessing sputum inflammatory markers may have
provided important additional information regarding not
only the efficacy of MK-0633 in COPD, but also the rela-
tionship between such markers and clinical severity of
COPD. However, such an analysis was beyond the scope of
this Phase II study.
In conclusion, the 5-LO inhibitor MK-0633 was not
significantly more effective than placebo in improving FEV1
from baseline in patients with COPD, although more
patients reported feeling improved with MK-0633.
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